0001193125-21-241250 | 6-K | XBRL Viewer

Print Document View Excel Document

Cover Page	6 Months Ended
Cover Page	Jun. 30, 2021
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2
Entity Registrant Name	Immatics N.V.
Entity Central Index Key	0001809196
Current Fiscal Year End Date	--12-31

Condensed Consolidated Statement of Financial Position of Immatics N.V. - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	€ 160,093	€ 207,530
Other financial assets	32,712	24,448
Accounts receivable	718	1,250
Other current assets	4,815	5,763
Total current assets	198,338	238,991
Non-current assets
Property, plant and equipment	8,747	7,868
Intangible assets	1,262	914
Right-of-use assets	7,313	6,149
Other non-current assets	845	724
Total non-current assets	18,167	15,655
Total assets	216,505	254,646
Current liabilities
Provisions	1,960	51
Accounts payable	9,407	10,052
Deferred revenue	57,998	46,600
Lease liabilities	2,321	1,881
Other current liabilities	1,442	2,025
Total current liabilities	73,128	60,609
Non-current liabilities
Deferred revenue	62,201	85,475
Lease liabilities	4,736	4,306
Total non-current liabilities	66,937	89,781
Shareholders' equity
Share capital	629	629
Share premium	589,609	573,339
Accumulated deficit	(507,663)	(462,253)
Other reserves	(6,135)	(7,459)
Total shareholders' equity	76,440	104,256
Total liabilities and shareholders' equity	€ 216,505	€ 254,646

Condensed Consolidated Statement of Loss of Immatics N.V. - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Profit or loss [abstract]
Revenue from collaboration agreements	€ 5,189	€ 6,896	€ 12,592	€ 13,936
Research and development expenses	(20,340)	(16,505)	(43,389)	(28,751)
General and administrative expenses	(8,271)	(10,076)	(16,702)	(16,264)
Other income	26	86	265	200
Operating result	(23,396)	(19,599)	(47,234)	(30,879)
Financial income	213	437	3,101	1,083
Financial expenses	(629)	(2,164)	(1,277)	(110)
Financial result	(416)	(1,727)	1,824	973
Loss before taxes	(23,812)	(21,326)	(45,410)	(29,906)
Taxes on income		0		0
Net loss	(23,812)	(21,326)	(45,410)	(29,906)
Attributable to:
Equity holders of the parent	(23,812)	(21,043)	(45,410)	(29,349)
Non-controlling interest		(283)		(557)
Net loss	€ (23,812)	€ (21,326)	€ (45,410)	€ (29,906)
Net loss per share—basic and diluted	€ (0.38)	€ (0.64)	€ (0.72)	€ (890)
Weighted average shares outstanding—basic and diluted	62,909,095	33,093,838	62,908,945	33,093,838

Condensed Consolidated Statement of Comprehensive Loss of Immatics N.V. - EUR (€) € in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Statement of comprehensive income [abstract]
Net Loss	€ (23,812)	€ (21,326)	€ (45,410)	€ (29,906)
Items that may be reclassified subsequently to profit or loss, net of tax
Currency translation differences from foreign operations	(1,401)	791	1,324	99
Total comprehensive loss for the period	(25,213)	(20,535)	(44,086)	(29,807)
Attributable to:
Equity holders of the parent	(25,213)	(20,252)	(44,086)	(29,250)
Non-controlling interest		(283)		(557)
Total comprehensive loss for the period	€ (25,213)	€ (20,535)	€ (44,086)	€ (29,807)

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2020-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2020-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2020-01-01

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2020-01-01

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2020-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2020-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2020-01-01

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2020-01-01

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2020-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2020-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2020-01-01

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2020-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2020-en-r&anchor=para_23&doctype=Standard
-URIDate 2020-01-01

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2020-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2020-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2020-01-01

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2020-01-01

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2020-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2020-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2020-01-01

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2020-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2020-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2020-01-01

+ Details

Condensed Consolidated Statement of Cash Flows of Immatics N.V. - EUR (€) € in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities
Loss before taxation	€ (45,410)	€ (29,906)
Adjustments for:
Interest income	(87)	(755)
Depreciation and amortization	2,264	2,288
Interest expense	140	110
Equity settled share-based payment	16,270	6,928
MD Anderson compensation expense		45
Increase in other liabilities resulting from share appreciation rights		7,773
Cash-out related to share-based compensation previously classified as equity-settled		(4,322)
Net foreign exchange differences	236	1
Changes in working capital
Decrease in accounts receivable	532	530
Decrease/(increase) in other assets	902	(1,106)
Increase in accounts payable and other current liabilities	(11,363)	(9,724)
Interest received	54	510
Interest paid	(140)	(110)
Net cash used in operating activities	(36,602)	(27,738)
Cash flows from investing activities
Payments for property, plant and equipment	(1,912)	(4,514)
Cash paid for investments classified in Other financial assets	(53,782)	(32,859)
Cash received from maturity of investments classified in Other financial assets	45,770	48,881
Payments for intangible assets	(390)	(36)
Proceeds from disposal of property, plant and equipment	8	0
Net cash (used in)/provided by investing activities	(10,306)	11,472
Cash flows from financing activities
Payments for leases	(1,348)	(1,168)
Net cash used in financing activities	(1,348)	(1,168)
Net decrease in cash and cash equivalents	(48,256)	(17,434)
Cash and cash equivalents at beginning of period	207,530	103,353
Effects of exchange rate changes on cash and cash equivalents	819	137
Cash and cash equivalents at end of period	€ 160,093	€ 86,056

Condensed Consolidated Statement of Changes in Shareholders' equity (deficit) of Immatics N.V. - EUR (€) € in Thousands	Total	Share capital [member]	Share premium [member]	Accumulated deficit [member]	Other reserves [member]	Total equity (deficit) attributable to shareholders of the parent [member]	Non-controlling interests [member]
Beginning Balance at Dec. 31, 2019	€ (40,835)	€ 1,164	€ 190,945	€ (233,194)	€ (770)	€ (41,855)	€ 1,020
Other comprehensive income (loss)	99				99	99
Net Loss	(29,906)			(29,349)		(29,349)	(557)
Comprehensive income/(loss) for the year	(29,807)			(29,349)	99	(29,250)	(557)
Equity-settled share-based compensation	6,928		6,928			6,928
Cash-out related to share-based compensation previously classified as equity-settled	(4,322)		(4,322)			(4,322)
MD Anderson milestone compensation expense	45						45
Ending Balance at Jun. 30, 2020	(67,991)	1,164	193,551	(262,543)	(671)	(68,499)	€ 508
Beginning Balance at Dec. 31, 2020	104,256	629	573,339	(462,253)	(7,459)	104,256
Other comprehensive income (loss)	1,324				1,324	1,324
Net Loss	(45,410)			(45,410)		(45,410)
Comprehensive income/(loss) for the year	(44,086)			(45,410)	1,324	(44,086)
Equity-settled share-based compensation	16,270		16,270			16,270
Ending Balance at Jun. 30, 2021	€ 76,440	€ 629	€ 589,609	€ (507,663)	€ (6,135)	€ 76,440

- Definition

The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.

+ References + Details

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

+ Details

Group information

6 Months Ended

Jun. 30, 2021

Group information - Additional Information (Detail)		3 Months Ended	6 Months Ended
Group information - Additional Information (Detail)	Aug. 10, 2021	Jun. 30, 2021	Jun. 30, 2021
Disclosure of non-adjusting events after reporting period [line items]
Date of end of reporting period		Jun. 30, 2021	Jun. 30, 2021
Authorization Of Financial Statements [Member]
Disclosure of non-adjusting events after reporting period [line items]
Date of authorisation for issue of financial statements	Aug. 05, 2021

Significant accounting policies - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2020
Immatics US Inc [Member]
Disclosure of subsidiaries [line items]
Ownership interests held by non-controlling interests	3.96%

Other current assets -Summary of Other current assets (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Trade and other receivables [abstract]
Grant receivable	€ 726	€ 875
Prepaid expenses	1,821	2,389
Positive market value forward contract	9	914
Value added tax receivable	1,240	798
Other assets	1,019	787
Other current assets	€ 4,815	€ 5,763

Other current assets - Additional Information (Details) - EUR (€) € in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Disclosure of Other Current Assets [Line Items]
Prepaid insurance expenses	€ 200	€ 1,000
Prepaid expenses of licenses and software	500	600
Other assets	1,019	787
Receivables From Capital Gains Tax [Member]
Disclosure of Other Current Assets [Line Items]
Other assets	400	400
Celgene Switzerland LLC And Genmab AS [Member]
Disclosure of Other Current Assets [Line Items]
Current Incremental cost for collaboration agreement	€ 600	€ 500

Revenue from collaboration agreements - Summary of Deferred revenue related to the collaboration agreements (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Revenue [abstract]
Current	€ 57,998	€ 46,600
Non-current	62,201	85,475
Total	€ 120,199	€ 132,075

Income Tax - Additional Information (Detail) - EUR (€)	3 Months Ended		6 Months Ended
Income Tax - Additional Information (Detail) - EUR (€)	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Statements [Line Items]
statutory tax rate	29.10%	29.10%	29.10%	29.10%
corporate income tax rate	21.00%	21.00%	21.00%	21.00%
Deferred Tax Assets Recognized In Respect Of Losses Due To Uncertainty [Member]
Statements [Line Items]
Deferred tax assets	€ 0		€ 0		€ 0

Provisions - Summary of Provisions (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Provisions [abstract]
Other provision	€ 50	€ 51
Provision for bonuses	1,910
Total provisions	€ 1,960	€ 51

Other current liabilities - Summary of other current liabilities (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of detailed information about other current liabilities [Line Items]
Payroll tax	€ 296	€ 1,185
Accrual for vacation	1,021	525
Accrued bonuses		154
Other	125	161
Total	€ 1,442	€ 2,025

Share-based payments - Summary of Options Granted Priced Using Black Scholes for SARs, Tandem Awards, Converted Options, Matching Stock Options and Monte Carlo Option Pricing Model (Detail) - Additional Grants Under 2020 Plan [Member]	Jun. 29, 2021 yr $ / shares	Jun. 17, 2021 yr $ / shares	Mar. 30, 2021 yr $ / shares
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price	$ 11.93	$ 12.05	$ 11.68
Underlying share price	$ 11.93	$ 12.05	$ 11.68
Volatility	84.53%	84.67%	85.77%
Time period (years) \| yr	6.10	6.11	6.1
Risk free rate	1.08%	1.10%	1.17%
Dividend yield	0.00%	0.00%	0.00%

Share-based payments - Summary of Employee Share Options (Detail)	3 Months Ended	6 Months Ended
	Jun. 30, 2021 shares $ / shares	Jun. 30, 2021 shares $ / shares
Performance Based Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares		$ 10.00
SARs forfeited \| $ / shares		10.00
Weighted average exercise price, Outstanding at June 30, \| $ / shares	$ 10.00	10.00
SARs vested \| $ / shares	$ 0	$ 0
Number of share options, outstanding at January 1,		3,644,000
SARs granted	0	0
SARs forfeited		12,000
Number of share options, outstanding at June 30,	3,632,000	3,632,000
SARs vested	0	0
Weighted average remaining contract life (years)		9 years 1 month 9 days
Additional Grants Under 2020 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares		$ 9.87
SARs forfeited \| $ / shares		10.46
SARs exercised \| $ / shares		0
SARs expired \| $ / shares		0
Weighted average exercise price, Outstanding at June 30, \| $ / shares	$ 10.65	10.65
SARs vested \| $ / shares	$ 0	$ 0
Number of share options, outstanding at January 1,		1,910,182
SARs forfeited		109,110
SARs exercised		0
SARs expired		0
Number of share options, outstanding at June 30,	1,967,377	1,967,377
SARs vested	0	0
Weighted average remaining contract life (years)		9 years 6 months 25 days
Additional Grants Under 2020 Plan [Member] \| Granted On March 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted \| $ / shares		$ 11.68
SARs granted		90,325
Additional Grants Under 2020 Plan [Member] \| Granted On June 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
SARs granted \| $ / shares		$ 11.99
SARs granted		75,980
Converted Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares		$ 2.58
SARs forfeited \| $ / shares		1.20
SARs exercised \| $ / shares		1.25
SARs expired \| $ / shares		1.20
Weighted average exercise price, Outstanding at June 30, \| $ / shares	$ 2.47	2.47
SARs vested \| $ / shares	$ 2.49	$ 2.49
Number of share options, outstanding at January 1,		594,844
SARs forfeited		16,958
SARs exercised		734
SARs expired		1,637
Number of share options, outstanding at June 30,	575,515	575,515
SARs vested	99,211	99,211
Weighted average remaining contract life (years)		6 years 6 months 3 days
Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Weighted average exercise price, Outstanding at January 1, \| $ / shares		$ 10.00
SARs forfeited \| $ / shares		10.00
Weighted average exercise price, Outstanding at June 30, \| $ / shares	$ 10.00	10.00
SARs vested \| $ / shares	$ 10.00	$ 10.00
Number of share options, outstanding at January 1,		1,422,556
SARs forfeited		9,254
Number of share options, outstanding at June 30,	1,413,302	1,413,302
SARs vested	38,702	38,702
Weighted average remaining contract life (years)		9 years 3 days

Share-based payments - Additional Information (Detail) $ / shares in Units, € in Thousands, $ in Billions				3 Months Ended		6 Months Ended
	Jun. 29, 2021 $ / shares	Jun. 17, 2021 $ / shares	Mar. 30, 2021 $ / shares	Jun. 30, 2021 EUR (€) shares	Jun. 30, 2020 EUR (€)	Jun. 30, 2021 EUR (€) shares	Jun. 30, 2021 USD ($) $ / shares	Jun. 30, 2020 EUR (€)
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense \| €				€ 7,965	€ 8,691	€ 16,269		€ 9,419
Performance Based Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted \| shares				0		0
Performance Based Options [Member] \| Tranche One [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Minimum market capitalization \| $							$ 1.5
Performance Based Options [Member] \| Tranche Two [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Minimum market capitalization \| $							2.0
Performance Based Options [Member] \| Tranche Three [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Minimum market capitalization \| $							$ 3.0
Additional Grants Under 2020 Plan [Member] \| Granted On March 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted \| shares						90,325
Share based compensation by share based payment arrangement exercise price per share granted							$ 11.68
Share based compensation by share based payment arrangement fair value per share			$ 8.48
Additional Grants Under 2020 Plan [Member] \| Granted On June 2021 [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Number of options granted \| shares						75,980
Share based compensation by share based payment arrangement exercise price per share granted							11.99
Share based compensation by share based payment arrangement fair value per share	$ 8.48	$ 8.48
Matching Stock Options [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share based compensation by share based payment arrangement exercise price per share granted							$ 10
Share based compensation by share based payment arrangement term of stock options						ten-year
Date of vesting of stock options						Jul. 31, 2021
2010 and 2016 Plan
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense \| €								800
2010 and 2016 Plan \| Cash Settled Award [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense \| €								700
2010 and 2016 Plan \| Equity Settled Award [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Share-based compensation expense \| €								€ 100

Related party disclosures - Additional Information (Detail) - shares		6 Months Ended
	Jun. 17, 2021	Jun. 30, 2021
Disclosure of transactions between related parties [line items]
Description of Transactions with related party		During the three and six months ended June 30, 2021 the Group did not enter into any new related-party transactions with its key management personnel or with related entities other than renewed service contracts for members of the Supervisory Board based on their election at the Annual General Meeting held on June 17, 2021. As part of his election, Dr. Friedrich von Bohlen und Halbach has been granted 25,000 Service Options.
Dr. Friedrich Von Bohlen Und Halbach [Member]
Disclosure of transactions between related parties [line items]
Related party transaction, Options granted	25,000

Financial Instruments - Summary of Carrying Amounts and Fair values of Group's Financial Instruments (Detail) - EUR (€) € in Thousands	Jun. 30, 2021	Dec. 31, 2020
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	€ 34,017	€ 28,198
Financial liabilities, Carrying amount	10,849	12,077
Financial assets, Fair value	34,008	28,198
Financial liabilities, Fair value	10,849	12,077
Financial assets at fair value through profit or loss, category [member] \| Positive Market Value Forward Contracts [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	9	914
Financial assets, Fair value	9	914
Financial assets at fair value through profit or loss, category [member] \| Negative Market Value Forward Contracts [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	40	0
Financial liabilities, Fair value	40	0
Other Financial Assets At Amortized Cost [Member] \| ShortTerm Deposits [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	21,037	24,448
Financial assets, Fair value	21,037	24,448
Other Financial Assets At Amortized Cost [Member] \| Bonds [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	11,675	0
Financial assets, Fair value	11,666	0
Other Financial Assets At Amortized Cost [Member] \| Trade receivables [member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	718	1,250
Financial assets, Fair value	718	1,250
Other Financial Assets At Amortized Cost [Member] \| Other current/non-current assets [Member]
Disclosure of detailed information about financial instruments [line items]
Financial assets, Carrying amount	578	1,586
Financial assets, Fair value	578	1,586
Other Financial Assets At Amortized Cost [Member] \| Accounts Payable [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	9,407	10,052
Financial liabilities, Fair value	9,407	10,052
Other Financial Assets At Amortized Cost [Member] \| Other Current Liabilities [Member]
Disclosure of detailed information about financial instruments [line items]
Financial liabilities, Carrying amount	1,402	2,025
Financial liabilities, Fair value	€ 1,402	€ 2,025